Soleno Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	96.04	20.89	-175.85	-38.99	-24.07	-30.91
Depreciation & Amortization	2.03	2.02	1.99	1.96	1.96	1.96
Stock-Based Compensation	47.22	45.85	99.96	5.95	2.53	3.28
Other Adjustments	0.88	2.68	-1.21	3.22	-0.45	-0.95
Change in Receivables	-47.14	-28.21	-	-	-	-
Changes in Inventories	-15.86	-14.03	-	-	-	-
Changes in Accounts Payable	3.98	3.61	5.67	1.37	-1.48	-0.24
Changes in Accrued Expenses	1.46	4.9	1.64	1.46	0.75	-0.65
Changes in Other Operating Activities	16.94	9.09	-1.3	0.1	-0.03	-0.27
Operating Cash Flow	105.53	46.8	-69.1	-24.94	-20.78	-27.77
Capital Expenditures	-0.11	-0.07	-0.22	-	-0.01	-0.02
Purchases of Investments	-511.69	-455.78	-356.46	-	-	-
Proceeds from Sale of Investments	325.06	254.07	131	-	-	-
Investing Cash Flow	-186.74	-201.78	-225.68	-	-0.01	-0.02
Long-Term Debt Issued	-	-	49.89	-	-	-
Net Long-Term Debt Issued (Repaid)	-	-	49.89	-	-	-
Issuance of Common Stock	240.07	238.11	163.14	180.02	14.11	-
Repurchase of Common Stock	-0.75	-100.89	-	-	-0.02	-0.12
Net Common Stock Issued (Repurchased)	239.32	137.22	163.14	180.02	14.09	-0.12
Other Financing Activities	-1.18	-0.06	-	-	-	-0.01
Financing Cash Flow	132.9	137.16	213.03	180.02	14.09	-0.13
Net Cash Flow	51.7	-17.82	-81.75	155.08	-6.7	-27.92
Free Cash Flow	105.42	46.73	-69.31	-24.94	-20.79	-27.79
Free Cash Flow Growth	125.62%	-	-	-	-	-
FCF Margin	36.99%	24.54%	-	-	-	-
Free Cash Flow Per Share	1.98	0.89	-1.73	-1.51	-2.48	-5.23
Levered Free Cash Flow	104.48	25.99	-118.18	-34.1	-22.87	-30.12
Unlevered Free Cash Flow	91.81	14.93	-179.88	-36.5	-23.2	-30.74

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q